Skip to main content
Premium Trial:

Request an Annual Quote

Affomix, U Montreal PGx Centre, and Montreal Heart Institute Ink PGx Deal

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Antibody company Affomix today announced a collaboration with the University of Montreal Pharmacogenomics Centre and the Montreal Heart Institute to develop companion diagnostic biomarkers for cardiovascular disease.

Under the agreement, the financial terms of which were not disclosed, Affomix and the PGx Centre will partner to develop reagents for the quantitative profiling of candidate biomarkers in a multiplex manner. The PGx Centre has identified a panel of proteins it believes may be predictive of patient response to novel anti-atherosclerotic agents.

In a statement, Jean-Claude Tardif, director of the Research Center at the Montreal Heart Institute, said, "Having the ability to consistently measure these cardiovascular proteins represents a key first step in identifying important biomarkers that will help us better understand atherosclerosis and how patients respond to certain medications."

Based in Branford, Conn., Affomix develops monoclonal antibodies using its proprietary technology, called Y2H Express, that it says improves upon traditional yeast two-hybrid technology in terms of antibody specificity.

In January, Affomix and the City of Hope announced a collaboration to determine the clinical use of "digital proteomics" using next-generation sequencing. In December, it signed an agreement with Kalgene Pharmaceuticals to select antibodies with potential diagnostic and therapeutic use in breast cancer.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.